Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial

Karim Fizazi, Arun Azad, Nobuaki Matsubara, Joan Carles, André P. Fay, Ugo De Giorgi, Jae Young Joung, Peter C.C. Fong, Éric Voog, Robert J. Jones, Neal D. Shore, Curtis Dunshee, Stefanie Zschäbitz, Jan Oldenburg, Dingwei Ye, Xun Lin, Matko Kalac, Alexander Laird, Dana A. Kennedy, Neeraj Agarwal